Ensign Peak Advisors Inc Has $41.70 Million Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Ensign Peak Advisors Inc lifted its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 44.5% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 1,646,202 shares of the company’s stock after buying an additional 506,845 shares during the quarter. Ensign Peak Advisors Inc owned about 0.88% of BridgeBio Pharma worth $41,698,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. lifted its position in BridgeBio Pharma by 3.3% during the first quarter. Vanguard Group Inc. now owns 13,222,126 shares of the company’s stock worth $408,828,000 after acquiring an additional 421,832 shares during the last quarter. Janus Henderson Group PLC grew its holdings in BridgeBio Pharma by 189.7% in the 1st quarter. Janus Henderson Group PLC now owns 3,312,706 shares of the company’s stock valued at $102,402,000 after buying an additional 2,169,143 shares in the last quarter. Capital Research Global Investors increased its position in BridgeBio Pharma by 101.1% during the 1st quarter. Capital Research Global Investors now owns 2,212,085 shares of the company’s stock worth $68,398,000 after buying an additional 1,111,975 shares during the period. Wellington Management Group LLP lifted its holdings in shares of BridgeBio Pharma by 5.3% during the fourth quarter. Wellington Management Group LLP now owns 1,495,114 shares of the company’s stock worth $60,358,000 after buying an additional 75,564 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of BridgeBio Pharma in the fourth quarter valued at about $46,843,000. Institutional investors own 99.85% of the company’s stock.

Analyst Ratings Changes

BBIO has been the topic of a number of recent research reports. UBS Group lowered their price target on shares of BridgeBio Pharma from $51.00 to $47.00 and set a “buy” rating on the stock in a research report on Tuesday, May 28th. HC Wainwright reiterated a “buy” rating and issued a $43.00 price target on shares of BridgeBio Pharma in a research report on Monday, September 16th. Cantor Fitzgerald reissued an “overweight” rating and set a $70.00 price target on shares of BridgeBio Pharma in a research report on Monday, September 16th. JPMorgan Chase & Co. lowered their price objective on BridgeBio Pharma from $46.00 to $43.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 7th. Finally, Evercore ISI cut their target price on BridgeBio Pharma from $50.00 to $45.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $47.92.

BridgeBio Pharma Stock Down 0.3 %

NASDAQ:BBIO opened at $26.74 on Friday. BridgeBio Pharma, Inc. has a twelve month low of $21.62 and a twelve month high of $44.32. The stock’s 50-day simple moving average is $26.50 and its 200 day simple moving average is $27.17. The firm has a market capitalization of $5.00 billion, a PE ratio of -8.30 and a beta of 1.07.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.61. The company had revenue of $2.17 million during the quarter, compared to analyst estimates of $3.96 million. The company’s revenue for the quarter was up 32.1% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.98) earnings per share. On average, analysts anticipate that BridgeBio Pharma, Inc. will post -2.49 EPS for the current fiscal year.

Insider Buying and Selling at BridgeBio Pharma

In other news, CEO Neil Kumar sold 27,389 shares of the stock in a transaction on Monday, August 19th. The stock was sold at an average price of $24.69, for a total value of $676,234.41. Following the completion of the transaction, the chief executive officer now directly owns 4,897,443 shares in the company, valued at approximately $120,917,867.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Neil Kumar sold 27,389 shares of the business’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $24.69, for a total transaction of $676,234.41. Following the sale, the chief executive officer now directly owns 4,897,443 shares in the company, valued at $120,917,867.67. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $25.75, for a total transaction of $149,350,000.00. Following the completion of the transaction, the insider now owns 25,260,971 shares of the company’s stock, valued at approximately $650,470,003.25. The disclosure for this sale can be found here. Insiders have sold 5,831,544 shares of company stock worth $150,128,821 over the last quarter. Corporate insiders own 24.66% of the company’s stock.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.